e-learning
resources
Barcelona 2013
Monday, 09.09.2013
COPD mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Granulocytic myeloid-derived-supressor cells (GrMDSCs) in chronic obstructive pulmonary disease (COPD) patients
A. Nowicka, B. Brajer-Luftmann, M. Kaczmarek, H. Batura-Gabryel (Poznan, Poland)
Source:
Annual Congress 2013 –COPD mechanisms
Session:
COPD mechanisms
Session type:
Thematic Poster Session
Number:
2156
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Nowicka, B. Brajer-Luftmann, M. Kaczmarek, H. Batura-Gabryel (Poznan, Poland). Granulocytic myeloid-derived-supressor cells (GrMDSCs) in chronic obstructive pulmonary disease (COPD) patients. Eur Respir J 2013; 42: Suppl. 57, 2156
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Subpopulation structure of lymphocytes in patients with chronic obstructive pulmonary disease (COPD) during exacerbation and after treatment
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
Phenotype of T cells in lung tissue from smokers with or without chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 53s
Year: 2005
Local and systemic inflammation in chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –Biomarkers in asthma and COPD
Year: 2013
The state of patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2007; 30: Suppl. 51, 547s
Year: 2007
Emphysematous phenotype is an independent predictor for frequent exacerbation of chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD
Year: 2014
Platelets activation during chronic obstructive pulmonary disease (COPD) exacerbation
Source: Eur Respir J 2002; 20: Suppl. 38, 89s
Year: 2002
Bronchial fibrocyte-like cells accumulate in chronic obstructive pulmonary disease (COPD) lungs.
Source: ERS Lung Science Conference 2018
Year: 2018
Airway T-lymphocytes expressing IFN-γ are reduced in smokers with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 6s
Year: 2002
Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Low circulating CD34+ cells in chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2005; 26: Suppl. 49, 362s
Year: 2005
Survivin in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Lung volume response to bronchodilators is dependent on the stage of the disease in chronic obstructive pulmonary disease (COPD) patients
Source: Annual Congress 2006 - COPD therapy
Year: 2006
The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – COPD markers
Year: 2014
Chronic obstructive pulmonary disease (COPD) patients with bronchiectasis: clinical features?
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Influence of systemic inflammation and hypoxaemia on bone metabolism in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Periostin levels in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
Early phenotypes of chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Different data in COPD
Year: 2015
To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept